Finance entity
All 2 tracked stories fall under one category: markets. Of the tracked stories, 2 of 2 also mention Novo Nordisk, the most common co-covered peer. Across a 184-day span, the pace is roughly 0.1 stories per week. The 7.5 average consequence score is above the beat benchmark of 6.1 in the same window.
Last mentioned: Sep 24, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: markets. Of the tracked stories, 2 of 2 also mention Novo Nordisk, the most common co-covered peer. Across a 184-day span, the pace is roughly 0.1 stories per week. The 7.5 average consequence score is above the beat benchmark of 6.1 in the same window. They are less corroborated than the beat average, carrying 2.5 original sources each against 2.8 for the same window. Semaglutide appears in 2 tracked Finance stories published from March 25, 2026 through September 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 2019 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Semaglutide. Shared-story counts are live from our verified record — not editorial picks.
Nearly 1,000 product-liability cases in New Jersey and dozens more federally expose Novo Nordisk and Eli Lilly to potential legal costs and label changes, adding a new risk layer to the GLP-1 growth story.
India's pharmaceutical sector has launched a massive rollout of affordable versions of popular weight-loss medications, targeting the global dominance of high-priced GLP-1 agonists. This move threatens the premium pricing models of Western pharmaceutical giants while significantly expanding patient access in price-sensitive emerging markets.
Semaglutide is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
